Should Drug Companies Be Advertising to Consumers?

Tamar Abrams had a lousy couple of years in 2022 and ’23. Both her parents died; a relationship ended; she retired from communications consulting. She moved from Arlington, Virginia, to Warren, Rhode Island, where she knew all of two people. “I was kind of a mess,” recalled Abrams, 69. Trying to cope, “I was eating…

Read More

Links

FDA reverses its decision and will now review the Moderna flu vaccine.Could Australia be a model for FDA reform?“Pharma signals it’s done negotiating”Giant viruses.Hairy ball theorem.

Read More

Can We Ride the GenAI Wave Without Getting Subsumed by It?

By DAVID SHAYWITZ “There are decades where nothing happens; and there are weeks where decades happen,” said Lenin, probably never.  It’s also a remarkably apt characterization of the last year in generative AI (genAI) — the last week in particular — which has seen the AI landscape shift so dramatically that even skeptics are now updating…

Read More

Decoding the PBM Reform Provisions of the 2026 Consolidated Appropriations Act

After years of legislative debate, Congress has formally codified PBM reform into federal statute. Tucked within the Consolidated Appropriations Act, 2026 (H.R. 7148), signed on February 3, 2026 are structural mandates that will reshape Pharmacy Benefit Manager (PBM) operations in Medicare Part D and the commercial sector by 2028. The legislation targets three primary pillars:…

Read More

Red and Blue States Alike Want To Limit AI in Insurance. Trump Wants To Limit the States.

It’s the rare policy question that unites Republican Gov. Ron DeSantis of Florida and the Democratic-led Maryland government against President Donald Trump and Gov. Gavin Newsom of California: How should health insurers use AI? Regulating artificial intelligence, especially its use by health insurers, is becoming a politically divisive topic, and it’s scrambling traditional partisan lines….

Read More